References in periodicals archive ?
The most important therapeutic intervention is where the CRAO is associated with giant cell arteritis (GCA) and high dose systemic steroids must be administered before the fellow eye is affected.
The underlying cause of the CRAO needs to be determined and effective treatment of this will reduce the risk of repeat vascular occlusion in the same, or a fellow, eye as well as preventing other associated conditions such as stroke.
Patients with CRAO usually present with a sudden significant loss of vision, an afferent pupillary defect, diffuse retinal whitening, and the resultant classic 'cherry spot' on the macula.
Ocular pathology may, however, present in this way if loss of vision in one eye has gone unnoticed until the second eye becomes affected, for example exudative AMD or CRAO in temporal arteritis.